BENZALKONIUM CHLORIDE 0.13%

N/A

Manufactured by Meijer, Inc.

3,369 FDA adverse event reports analyzed

Last updated: 2026-04-15

About BENZALKONIUM CHLORIDE 0.13%

BENZALKONIUM CHLORIDE 0.13% is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Meijer, Inc.. The most commonly reported adverse reactions for BENZALKONIUM CHLORIDE 0.13% include DRUG INEFFECTIVE, DRUG HYPERSENSITIVITY, CONDITION AGGRAVATED, ARTHRALGIA, THERAPY NON-RESPONDER. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BENZALKONIUM CHLORIDE 0.13%.

Top Adverse Reactions

DRUG INEFFECTIVE124 reports
DRUG HYPERSENSITIVITY116 reports
CONDITION AGGRAVATED112 reports
ARTHRALGIA110 reports
THERAPY NON RESPONDER110 reports
MUSCULOSKELETAL STIFFNESS108 reports
PAIN IN EXTREMITY108 reports
INFECTION107 reports
HEPATOTOXICITY105 reports
JOINT SWELLING105 reports
MUSCULOSKELETAL PAIN105 reports
NEOPLASM MALIGNANT105 reports
GASTROINTESTINAL TOXICITY104 reports
JOINT INJURY103 reports
PULMONARY TOXICITY103 reports
TREATMENT FAILURE102 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE98 reports
C REACTIVE PROTEIN ABNORMAL96 reports
ARTHROPATHY95 reports
DRUG INTOLERANCE91 reports
JOINT STIFFNESS90 reports
RHEUMATOID ARTHRITIS50 reports
OFF LABEL USE41 reports
PERIPHERAL SWELLING39 reports
THERAPEUTIC PRODUCT EFFECT DECREASED35 reports
CONTRAINDICATED PRODUCT ADMINISTERED34 reports
INFLAMMATION33 reports
PAIN30 reports
RASH23 reports
FATIGUE22 reports
OCULAR HYPERAEMIA22 reports
DYSPNOEA21 reports
NAUSEA20 reports
PYREXIA19 reports
EYE IRRITATION18 reports
MALAISE18 reports
ABDOMINAL PAIN17 reports
BACK PAIN16 reports
ERYTHEMA16 reports
DIARRHOEA15 reports
PRURITUS15 reports
SWELLING15 reports
TOXIC ANTERIOR SEGMENT SYNDROME15 reports
DRY EYE14 reports
EYE PAIN14 reports
HYPERSENSITIVITY14 reports
SKIN ULCER14 reports
DIZZINESS13 reports
INFUSION RELATED REACTION13 reports
INTERSTITIAL LUNG DISEASE13 reports
VISUAL IMPAIRMENT13 reports
WHEEZING13 reports
WHITE BLOOD CELL COUNT DECREASED13 reports
FEELING ABNORMAL12 reports
FOLLICULITIS12 reports
LIVER DISORDER12 reports
MEDICATION ERROR12 reports
PNEUMONIA12 reports
PRODUCT PREPARATION ERROR12 reports
SINUSITIS12 reports
WEIGHT DECREASED12 reports
ALLERGY TO CHEMICALS11 reports
ANAEMIA11 reports
ARTHRITIS11 reports
BURSITIS11 reports
C REACTIVE PROTEIN INCREASED11 reports
CONJUNCTIVAL SCAR11 reports
CONJUNCTIVITIS11 reports
CUSHINGOID11 reports
DRY MOUTH11 reports
FIBROMYALGIA11 reports
HAEMOGLOBIN DECREASED11 reports
HAND DEFORMITY11 reports
HEADACHE11 reports
QUALITY OF LIFE DECREASED11 reports
RASH PRURITIC11 reports
THROMBOSIS11 reports
TOXIC EPIDERMAL NECROLYSIS11 reports
UPPER RESPIRATORY TRACT INFECTION11 reports
ANTINUCLEAR ANTIBODY POSITIVE10 reports
ATELECTASIS10 reports
BONE DENSITY DECREASED10 reports
CREPITATIONS10 reports
DEFORMITY10 reports
FEELING JITTERY10 reports
FLANK PAIN10 reports
HYPERTENSION10 reports
IMPAIRED HEALING10 reports
IMPAIRED WORK ABILITY10 reports
JOINT EFFUSION10 reports
JOINT RANGE OF MOTION DECREASED10 reports
LUNG DISORDER10 reports
MUSCULAR WEAKNESS10 reports
MYALGIA10 reports
NODULE10 reports
PHOTOPHOBIA10 reports
PLEURITIC PAIN10 reports
RASH MACULO PAPULAR10 reports
RED BLOOD CELL COUNT DECREASED10 reports
RHEUMATOID NODULE10 reports

Report Outcomes

Out of 363 classified reports for BENZALKONIUM CHLORIDE 0.13%:

Serious 87.3%Non-Serious 12.7%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female233 (70.4%)
Male97 (29.3%)
Unknown1 (0.3%)

Reports by Age

Age 4230 reports
Age 3012 reports
Age 4410 reports
Age 707 reports
Age 767 reports
Age 626 reports
Age 756 reports
Age 776 reports
Age 816 reports
Age 435 reports
Age 595 reports
Age 615 reports
Age 665 reports
Age 685 reports
Age 715 reports
Age 114 reports
Age 544 reports
Age 584 reports
Age 604 reports
Age 674 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with BENZALKONIUM CHLORIDE 0.13%?

This profile reflects 3,369 FDA FAERS reports that mention BENZALKONIUM CHLORIDE 0.13%. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for BENZALKONIUM CHLORIDE 0.13%?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, DRUG HYPERSENSITIVITY, CONDITION AGGRAVATED, ARTHRALGIA, THERAPY NON-RESPONDER, MUSCULOSKELETAL STIFFNESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures BENZALKONIUM CHLORIDE 0.13%?

Labeling and FAERS entries often list Meijer, Inc. in connection with BENZALKONIUM CHLORIDE 0.13%. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.